2014 Report on Tuberculosis Research Funding Trends, 2005–2013. 2nd Edition May 18, 2015 By Mike Frick Edited by Mark Harrington and Andrea Benzacar From the Executive Summary Reader beware: funding data presented in this report may be less encouraging than…
For people with drug-resistant tuberculosis (DR-TB), generic linezolid may be a lifesaver. But only if quality-assured versions are available and affordable Erica Lessem As new drugs bedaquiline and delamanid offer renewed hope of treating DR-TB, doctors and programs are faced…
The time has come for U.S. tuberculosis programs to have full access to the Stop TB Partnership’s Global Drug Facility procurement and stockpile safety nets Kenyon Farrow Generic drugs can be credited with saving millions of lives by allowing for…
Hello Generics: A Drug by Any Other Name; The Road to Treatment Access; Safeguarding Against Stockouts; Generics vs. the Giant
By Erica Lessem and Lauren Volpert September 2014 I. Introduction Increasingly drug-resistant forms of tuberculosis (TB) are becoming more common worldwide, and few medicines are available to treat them.1 Newly developed TB drugs, such as bedaquiline and delamanid, offer some…
Tuberculosis (TB) continues to kill over a million people each year, and multidrug-resistant (MDR) TB is a growing problem with few treatment options. In April 2014, delamanid was approved by the European Medicines Agency (EMA) for the treatment of TB, becoming only the second new drug from a new drug class (after bedaquiline) to receive such approval in over forty years.
July 20, 2014 HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development Written by Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn…
UPDATE: December 18, 2014 Sound Science of Redesigned STREAM Trial Investigators of the STREAM trial have successfully redesigned Stage 2 of the study to address concerns raised in the original article (below). Published in our Spring 2014 issue, this…
Tax dollars are making it easier for the drug and diagnostics industry to develop and market essential TB products. Is the public getting a fair return on its investment? By Lindsay McKenna Motivating the pharmaceutical industry to step up and…
NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS Spring 2014 The April Fools' Issue: April 1. This is the day upon which we are reminded of what we are on the other three hundred and sixty-four. —Mark…